Great to be a part of YCharOS Inc.’s first annual symposium last week - an important meet-up of the YCharOS Industry Advisory Committee to discuss strategies to characterize antibodies against the entire human proteome. An ambitious yet vital project to improve reproducibility in scientific research and ultimately speed up progress towards better biological understanding and improved treatments and health outcomes for all 🙌 Find out more about the role of the Industry Advisory Committee, here: https://lnkd.in/eVrs6ZR6
Last week, we convened our inaugural face-to-face YCharOS meeting, bringing together representatives from Canadian funding agencies, antibody manufacturers, pharmaceutical companies, and academia at McGill University. The objective of the meeting was to strategize how to scale this academic initiative from testing antibodies for 100 proteins to the human proteome. Through panel discussions, reverse brainstorming (thanks Hannah C. – but is it typical to fill up the entire whiteboard in few minutes with potential future problems 😉), and various presentations, we identified several potential strategies that will require a few more weeks to digest. We'll provide a summary of the meeting along with our forward strategy. A big thank you to our antibody manufacturer partners—abcam, ABclonal Technology, Aviva Systems Biology,Bio-Techne, ABCD Antibodies, Cell Signaling Technology (CST), DSHB, GeneTex, Inc., Institute for Protein Innovation, Proteintech Group, Synaptic Systems GmbH, Thermo Fisher Scientific, YCharOS Inc. —for making the YCharOS project possible and for attending the meeting. Who can guess the type of IgG represented in that picture?